Regatul Unit - engleză - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - ixekizumab - solution for injection - 80mg/1ml

Israel - engleză - Ministry of Health

eli lilly israel ltd, israel - ixekizumab - solution for injection - ixekizumab 80 mg / 1 ml - ixekizumab - plaque psoriasis :taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.psoriatic arthritis : taltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (dmard) therapiesankylosing spondylitis (radiographic axial spondyloarthritis)taltz is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.non-radiographic axial spondyloarthritistaltz is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and magnetic resonance imaging (mri) who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids).

Singapore - engleză - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - ixekizumab - injection, solution - ixekizumab 80 mg/ml

Africa de Sud - engleză - South African Health Products Regulatory Authority (SAHPRA)

eli lilly (s.a.) (pty) ltd - injection - see ingredients - each 1,0 ml solution contains : ixekizumab 80,0 mg

Regatul Unit - engleză - MHRA (Medicines & Healthcare Products Regulatory Agency)

leo pharma - brodalumab - solution for injection - 140mg/1ml

Canada - engleză - Health Canada

bausch health, canada inc. - brodalumab - solution - 210mg - brodalumab 210mg - misc. skin and mucous membrane agents

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn. bhd. - guselkumab -

Uniunea Europeană - engleză - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressants - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards).crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Uniunea Europeană - engleză - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - immunosuppressants - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards).axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids).ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - bimekizumab, quantity: 160 mg/ml - injection - excipient ingredients: polysorbate 80; water for injections; glacial acetic acid; glycine; sodium acetate trihydrate - bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.